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Anaphylaxis is recently becoming an increas-
ingly popular issue among allergists, particularly 
upon fatigue with asthma matters. The paper 
“Anaphylaxis as a cause of hospitalization — 
a single academic centre experience” published 
in this issue of “Polish Pneumonology and Aller-
gology” follows this trend [1]. 
Anaphylaxis is a severe, life-threatening, 
generalised or systemic hypersensitivity reaction, 
with objective and repeatable symptoms triggered 
by a certain stimulus at a dose well tolerated by 
healthy individuals.
The origins of anaphylahysis do not date back 
to ancient times, as one author bantered about Pha-
raoh Menes who might have died from wasp sting 
[2]. Although anaphylaxis has been defined for the 
first time more than 100 years ago, to date it has 
not been included in international classifications 
of diseases. This fact has serious consequences, as 
while analysing the significance of the reaction, 
one cannot rely on data included in such classifica-
tions. In order to obtain elementary epidemiology 
rates and various clinical aspects of anaphylaxis, 
it is necessary to initiate dedicated studies.
American studies suggest that the notion of 
anaphylaxis is poorly known in the society [3]. 
As many as 7.7% of the respondents believed 
that they had an anaphylactic reaction, but 
verification proved that in 5.1% of cases it was 
probable, and solely in 1.6% certain. Not only 
the knowledge of patients but also the way they 
follow doctor’s orders cannot be considered sat-
isfying. At the beginning of the current century, 
food-induced anaphylaxis accounted merely for 
10% of cases, currently, particularly in Europe, it 
is believed to be a major factor causing anaphy-
laxis (more than 30%) [4]. It is worth mentioning 
that in approximately 30% of cases, anaphylaxis 
is triggered by the activity of at least two factors 
in close temporal relationship: allergen and/or 
physical exercise, cooling, alcohol consumption, 
medication, infection etc. These additional factors 
are referred to as cofactors [5].
On the one hand the risk of anaphylaxis 
depends on external factors, but on the other it 
depends on the properties of an organism. The 
highest individual risk of anaphylaxis occurs 
when it is necessary to reexpose the patient to 
a factor that is suspected to induce the episode 
of anaphylaxis (provocation tests, venom immu-
notherapy). It is known that women are at higher 
risk, which is caused by enhanced endothelial 
nitric oxide synthase through estrogen [6], ana-
phylaxis is also more common in people with 
mastocytosis [7] and those using beta blockers 
and/or ACE inhibitors [8]. The presented study 
has not confirmed more frequent occurrence 
of anaphylaxis in women, possibly because it 
analysed solely severe cases necessitating hos-
pitalisation.
Anaphylactic reactions may be mild (e.g. 
oral allergy syndrome, conditioned upon cross 
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reactivity of pollen allergens of plants, fruits, 
vegetables and cereal) or severe, life-threatening 
leading to anaphylactic shock (peanuts, insect 
venom). Specific properties that distinguish indi-
viduals who react so violently, are being sought. 
It seems that in such individuals, after the release 
of mediators from mast cells, a large quantity 
of platelet-activating factor is generated, with 
its strong vasoplegic qualities being the result 
of disordered cellular enzymatic mechanisms 
of this factor inactivation. And such persons 
being allergic e.g. to peanuts or insect venom, 
with platelet activating factor-acetylohydrolase 
defect, which is an enzyme restoring this fac-
tor to inactive form, often experience severe, 
life-threatening reactions [9, 10].
It is assumed that clinical picture of anaphy-
laxis, although heterogeneous, does not depend 
on the causative agent. The results of the pub-
lished study seem to confirm this theory. How-
ever, it should be emphasised that the episodes 
of anaphylaxis in the same patient may differ in 
the order of symptoms occurrence, particular 
organs affection, the course (severity), duration 
(phase) and effects (complications). Development 
of severe reactions, next to the properties of an 
organism, in great measure depends on the way of 
administration (activity) of the causative agent [11]. 
Yet even food-induced anaphylaxis may take 
a violent course, end with a death, although it 
may also develop slowly, last longer and pass 
through several phases, despite proper treatment. 
The most dangerous reactions are obstruction 
of the upper and lower airways (approximately 
50%) and cardiovascular events (about 35%), 
which may result in anaphylactic shock [12]. 
From a practical point of view, in the emergency 
setting, it is crucial to differentiate between severe 
anaphylaxis and vasovagal reaction (syncope). 
In the case of the latter, which is more common, 
contrary to anaphylaxis, the skin is generally cool 
and pale, there is no urticaria, oedema, pruritus, 
bronchial obstruction or nausea, but usually 
bradycardia occurs.
There are many studies regarding the man-
agement of severe anaphylaxis [12, 13]. Although 
help provided depends on the available possi-
bilities, the most important are the following: 
diagnosis, removal of the causative agent (if pos-
sible), assurance of the assistance of other people, 
assurance of patency of the airways. If adrenaline 
is available (a patient often possesses it), it should 
be administered. It is also vital to supplement 
liquids, give oxygen and assure that the patient 
is taken to hospital. Having the episode under 
control, the patient should receive adrenaline 
for self-administration and other medicines in 
the event of a future anaphylactic reaction. If 
the cause of the reaction remains unknown, the 
patient should be referred to an allergist in order 
to attempt to establish it. 
According to recently published studies, 
early prevention of allergy to peanuts, which is 
a common cause of fatal anaphylaxis, should start in 
4-month old infants from risk groups (eczema) [14]. 
Administration of small quantities of peanut but-
ter to such infants has decreased by 80% the risk 
of future allergy. The results of the studies are the 
next argument for earlier than it was believed, i.e. 
starting in the 4th month of life, introduction of 
solid food to the diet of infants. Unfortunately, the 
results of the researches regarding desensitization 
in food allergy have not brought about so spec-
tacular effects (oral immunotherapy), or they are 
still at early stages of investigation (epicutaneous 
immunotherapy) [15]. 
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